OPNT - Opiant's confirmatory pharmacokinetic study of OPNT003 gets underway

Opiant Pharma (OPNT) announced the dosing of the first patient in a confirmatory pharmacokinetic ((PK)) study for OPNT003, nasal nalmefene, for the treatment of opioid overdose, with study results expected by June 2021.The open label, randomized, crossover study will enroll 68 healthy volunteers and determine the pharmacokinetic profile of intranasally administered nalmefene compared to intramuscularly administered nalmefene.The company also said it plans to file a New Drug Application for OPNT003 with the U.S. FDA by the end of the year.Opiant shares up ~8% in after market trading.

For further details see:

Opiant's confirmatory pharmacokinetic study of OPNT003 gets underway